GlassScriptPhysician profile
Mijo Kim
NPI 1851000616
$6,066.10
in general payments reported to CMS, 2019-2025
35 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.00 · 2023: $1,990 · 2024: $2,644 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,047.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,002.95 | 2023-2025 | |
| Pfizer INC. | $777.86 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $714.43 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $385.19 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Ironwood Pharmaceuticals, INC | $335.35 | 2023-2025 | Linzess |
| Lilly USA, LLC | $324.88 | 2023-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $252.62 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $242.51 | 2022-2023 | |
| Novo Nordisk INC | $227.42 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Ardelyx, INC. | $206.77 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.18 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $170.40 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $131.24 | 2023-2025 | Auvelity, Symbravo |
| Uswm, LLC | $121.70 | 2023-2024 | Lucemyra, Zimhi |
| Aimmune Therapeutics, INC. | $119.92 | 2024-2025 | Zenpep |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $108.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $90.67 | 2024 | Otezla, Repatha |
| Viatris Specialty LLC | $80.31 | 2025 | Yupelri |
| Viiv Healthcare Company | $66.80 | 2023-2024 | Apretude, Dovato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.38 | 2023-2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.36 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $51.87 | 2024-2025 | |
| Glaxosmithkline, LLC. | $49.79 | 2024 | Shingrix, Arexvy |
| Qol Medical, LLC | $39.44 | 2024 | Sucraid |
| Vanda Pharmaceuticals INC. | $35.20 | 2025 | Fanapt |
| Paratek Pharmaceuticals, INC. | $34.29 | 2024 | Nuzyra |
| Ani Pharmaceuticals, INC. | $31.36 | 2025 | Purified Cortrophin Gel |
| Lundbeck LLC | $27.71 | 2023 | Rexulti |
| Daiichi Sankyo INC. | $27.30 | 2023 | Injectafer |
| Hologic Sales and Service, LLC | $24.28 | 2023 | Aptima |
| Mylan Specialty L.P. | $23.73 | 2024 | Yupelri |
| Inogen, INC. | $21.78 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Exeltis, USA INC. | $17.99 | 2023 | Slynd |
| Phathom Pharmaceuticals, INC. | $16.05 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $15.98 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mijo Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.